Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

University of California, San Francisco

ClinicalTrials.gov Identifier:

NCT01006005

First received: October 30, 2009

Last updated: November 20, 2012

Last verified: November 2012

History of Changes

Purpose

The study is recruiting 50 patients initiating or switching to Atripla and comparing them to 250 individuals previously followed in a prospective study of HIV+ low income individuals recruited from homeless shelters, single room occupancy hotels and free meal food lines as part of the UCSF Reach Study. Adherence will be measured through monthly unannounced pill counts and electronic medication monitors.

Condition
HIV Infections Adherence


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Atripla

U.S. FDA Resources

Further study details as provided by University of California, San Francisco:


Enrollment:	51
Study Start Date:	July 2007
Study Completion Date:	June 2008
Primary Completion Date:	June 2008 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

HIV infected, marginally housed

Criteria

Inclusion Criteria:

18+ years old;
HIV+;
Initiating Atripla within 6-months of recruitment;
Lives in the Tenderloin, South of Market, or Mission District San Francisco;
Capable of providing informed consent; and
Willing to complete all study procedures.

Exclusion Criteria:

Intoxication, cognitive dysfunction or psychosis will preclude potential subjects from informed consent.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided

More Information


Responsible Party:	University of California, San Francisco
ClinicalTrials.gov Identifier:	NCT01006005 History of Changes
Other Study ID Numbers:	IN-US-177-0106
Study First Received:	October 30, 2009
Last Updated:	November 20, 2012

Keywords provided by University of California, San Francisco:


HIV Treatment experienced

Additional relevant MeSH terms:


HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases	Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents

ClinicalTrials.gov processed this record on June 28, 2017

To Top